The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.

British journal of haematology 20120801

Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.

Haematologica 20120701

A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).

Breast cancer research and treatment 20120701

Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.

Bioorganic & medicinal chemistry letters 20120501

Tipifarnib-mediated suppression of T-bet-dependent signaling pathways.

Cancer immunology, immunotherapy : CII 20120401

Are low-intensity induction strategies better for older patients with acute myeloid leukemia?

Leukemia research 20120401

Kinase inhibitors for advanced medullary thyroid carcinoma.

Clinics (Sao Paulo, Brazil) 20120401

Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells.

Journal of cancer research and clinical oncology 20120301

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).

Clinical cancer research : an official journal of the American Association for Cancer Research 20120215

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.

Blood 20120105

Two genes, tipifarnib, and AML.

Blood 20120105

Molecular targets for the treatment of juvenile myelomonocytic leukemia.

Advances in hematology 20120101

Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

PloS one 20120101

Targeted agents for the treatment of metastatic melanoma.

OncoTargets and therapy 20120101

Novel therapies for aggressive B-cell lymphoma.

Advances in hematology 20120101

An overview of the evidence and mechanisms of herb-drug interactions.

Frontiers in pharmacology 20120101

Acute myeloid leukemia: focus on novel therapeutic strategies.

Clinical Medicine Insights. Oncology 20120101

Current knowledge on pancreatic cancer.

Frontiers in oncology 20120101

Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.

BMC cancer 20120101

A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.

International journal of radiation oncology, biology, physics 20111201

Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers.

Current genomics 20111201

Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.

Blood 20111103

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

Blood 20111103

A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.

Leukemia 20111001

Treatment of high-grade glioma in children and adolescents.

Neuro-oncology 20111001

Opposing effects of monomeric and pentameric C-reactive protein on endothelial progenitor cells.

Basic research in cardiology 20110901

Applicability of a 'Pick a Winner' trial design to acute myeloid leukemia.

Blood 20110901

The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.

Pediatric research 20110701

Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.

The Journal of pharmacology and experimental therapeutics 20110601

Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110501

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

The Journal of clinical endocrinology and metabolism 20110401

MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC).

Neuro-oncology 20110401

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Cancer 20110315

A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110301

Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas.

Neuro-oncology 20110301

Novel agents for the treatment of acute myeloid leukemia in the older patient.

Journal of the National Comprehensive Cancer Network : JNCCN 20110301

Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.

Pediatric blood & cancer 20110201

Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110201

Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.

Journal of biomedicine & biotechnology 20110101

DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 20110101

Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.

Current medicinal chemistry 20110101

Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.

BMC cancer 20110101

Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway.

Journal of experimental & clinical cancer research : CR 20110101

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.

Journal of hematology & oncology 20110101

Molecular characteristics of pancreatic ductal adenocarcinoma.

Pathology research international 20110101

Current developments in the therapy of protozoan infections.

The open medicinal chemistry journal 20110101

Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies.

Journal of thyroid research 20110101

Promising molecular targeted therapies in breast cancer.

Indian journal of pharmacology 20110101

Successful in vitro expansion and differentiation of cord blood derived CD34+ cells into early endothelial progenitor cells reveals highly differential gene expression.

PloS one 20110101

Current immunotherapeutic approaches in pancreatic cancer.

Clinical & developmental immunology 20110101

Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.

ISRN oncology 20110101

Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.

Blood 20101209

Farnesyltransferase inhibitors: where are we now?

Expert opinion on investigational drugs 20101201

Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.

Cancer letters 20101101

Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.

Journal of medicinal chemistry 20101014

Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi.

PLoS pathogens 20100901

Importance of molecular cell biology investigations in human medicine in the story of the Hutchinson-Gilford progeria syndrome.

Interdisciplinary toxicology 20100901

Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways.

Leukemia research 20100801

Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib.

Leukemia 20100601

Development of therapeutic agents for older patients with acute myelogenous leukemia.

Current opinion in investigational drugs (London, England : 2000) 20100601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100601

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Oncotarget 20100601

Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission.

The Korean journal of hematology 20100601

Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.

Journal of medicinal chemistry 20100527

Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.

Expert opinion on investigational drugs 20100501

Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].

Molecular cancer therapeutics 20100501

Identifying tightly regulated and variably expressed networks by Differential Rank Conservation (DIRAC).

PLoS computational biology 20100501

Novel therapies for myelodysplastic syndromes.

Hematology/oncology clinics of North America 20100401

Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.

PLoS neglected tropical diseases 20100401

Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.

Cancer chemotherapy and pharmacology 20100301

Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.

The oncologist 20100301

Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy.

Journal of molecular graphics & modelling 20100226

Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research 20100215

Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.

Journal of oncology 20100101

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights.

Journal of hematology & oncology 20100101

Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.

Journal of carcinogenesis 20100101

The role of radiotherapy in multimodal treatment of pancreatic carcinoma.

Radiation oncology (London, England) 20100101

Challenges in treating older patients with acute myeloid leukemia.

Journal of oncology 20100101

A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimetics.

Molecular cancer 20100101

Recent advances in the treatment of acute myeloid leukemia.

F1000 medicine reports 20100101

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine.

OncoTargets and therapy 20100101

Current and emerging therapies for the treatment of pancreatic cancer.

OncoTargets and therapy 20100101

Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms.

F1000 medicine reports 20100101

Current and developing therapeutic agents in the treatment of Chagas disease.

Drug design, development and therapy 20100101

Present and future evolution of advanced breast cancer therapy.

Breast cancer research : BCR 20100101

Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds database.

Bioinformation 20100101

New treatments for myelodysplastic syndromes.

Mediterranean journal of hematology and infectious diseases 20100101

Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents.

Bioorganic & medicinal chemistry letters 20091201

[Targeting KRAS pathway in NSCLC therapy].

Bulletin du cancer 20091201

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20091201

Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research 20091115

Current data and strategy in glioblastoma multiforme.

Journal of medicine and life 20091115

Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.

Annals of hematology 20091101

W7FW14F apomyoglobin amyloid aggregates-mediated apoptosis is due to oxidative stress and AKT inactivation caused by Ras and Rac.

Journal of cellular physiology 20091101

The histologic spectrum of epithelial neoplasms induced by sorafenib.

Journal of the American Academy of Dermatology 20090901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090901

Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

British journal of cancer 20090818

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

Blood 20090806

Small molecules and targeted therapies in distant metastatic disease.

Annals of oncology : official journal of the European Society for Medical Oncology 20090801

New, improved treatments for Chagas disease: from the R&D pipeline to the patients.

PLoS neglected tropical diseases 20090701

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

Blood 20090514

Tipifarnib and etoposide for older AML patients: from bench to bedside.

Blood 20090514

Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090501

Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090415

Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation.

Annals of hematology 20090401

A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.

Leukemia 20090401

Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.

Annals of oncology : official journal of the European Society for Medical Oncology 20090401

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090401

Rational modification of a candidate cancer drug for use against Chagas disease.

Journal of medicinal chemistry 20090326

Synthesis and structure-activity relationships of novel benzofuran farnesyltransferase inhibitors.

Bioorganic & medicinal chemistry letters 20090315

Novel strategies for patients with chronic myeloproliferative disorders.

Current opinion in hematology 20090301

Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.

Journal of pain and symptom management 20090201

Applications of microarray technology to Acute Myelogenous Leukemia.

Cancer informatics 20090101

PrognoScan: a new database for meta-analysis of the prognostic value of genes.

BMC medical genomics 20090101

The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine.

Journal of experimental & clinical cancer research : CR 20090101

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.

Clinical interventions in aging 20090101

The ordering of expression among a few genes can provide simple cancer biomarkers and signal BRCA1 mutations.

BMC bioinformatics 20090101

Current available therapies and future directions in the treatment of malignant gliomas.

Biologics : targets & therapy 20090101

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.

Breast cancer research : BCR 20090101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090101

Two-transcript gene expression classifiers in the diagnosis and prognosis of human diseases.

BMC genomics 20090101

Managing myelodysplastic symptoms in elderly patients.

Clinical interventions in aging 20090101

Targeted therapy in the treatment of malignant gliomas.

OncoTargets and therapy 20090101

Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.

Neuro-oncology 20081201

Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling.

Blood 20081201

New agents for the treatment of AML recent study findings.

Clinical advances in hematology & oncology : H&O 20081101

Future research directions for the treatment of AML.

Clinical advances in hematology & oncology : H&O 20081101

A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.

Proceedings of the National Academy of Sciences of the United States of America 20081014

Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches.

Cancer control : journal of the Moffitt Cancer Center 20081001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20081001

Miscellaneous.

Indian journal of pharmacology 20081001

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.

Blood 20080915

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.

Biologics : targets & therapy 20080901

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.

Breast cancer research and treatment 20080701

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.

British journal of cancer 20080617

Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.

Neuro-oncology 20080601

Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.

Archives of dermatology 20080601

Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080515

Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.

British journal of haematology 20080501

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.

Molecular cancer therapeutics 20080501

Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.

Cancer chemotherapy and pharmacology 20080401

Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.

Clinical advances in hematology & oncology : H&O 20080401

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20080401

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.

Blood 20080301

Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.

International journal of radiation oncology, biology, physics 20080301

The potential effect of statins on rituximab immunotherapy.

PLoS medicine 20080301

Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080115

Inhibition of oncogene-induced inflammatory chemokines using a farnesyltransferase inhibitor.

Journal of inflammation (London, England) 20080101

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

BMC cancer 20080101

Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas.

Molecular cancer 20080101

Estimation and testing for the effect of a genetic pathway on a disease outcome using logistic kernel machine regression via logistic mixed models.

BMC bioinformatics 20080101

Molecular targeted therapies for breast cancer treatment.

Breast cancer research : BCR 20080101

In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors.

Acta haematologica 20080101

A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.

Cancer 20071201

Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.

Current opinion in investigational drugs (London, England : 2000) 20071201

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20071201

The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.

Biologics : targets & therapy 20071201

Tipifarnib in the treatment of acute myeloid leukemia.

Biologics : targets & therapy 20071201

The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.

International journal of cancer 20071115

Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives.

Critical reviews in oncology/hematology 20071101

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.

Cancer 20071101

Tipifarnib in acute myeloid leukemia.

Drugs of today (Barcelona, Spain : 1998) 20071101

Femara and the future: tailoring treatment and combination therapies with Femara.

Breast cancer research and treatment 20071001

Decitabine in the treatment of myelodysplastic syndromes.

Therapeutics and clinical risk management 20071001

Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.

Blood 20070915

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.

Leukemia 20070901

Cloning and characterization of a human BCR/ABL-positive cell line, K562/RR, resistant to the farnesyltransferase inhibition by tipifarnib.

Experimental hematology 20070901

The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.

Molecular cancer therapeutics 20070901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070901

On the diversity of biological therapeutics.

Biologics : targets & therapy 20070901

The molecular genetics of breast cancer and targeted therapy.

Biologics : targets & therapy 20070901

Exposure-toxicity relationships for tipifarnib in cancer patients.

British journal of clinical pharmacology 20070801

Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.

International journal of radiation oncology, biology, physics 20070801

Exploiting signal transduction pathways in acute myelogenous leukemia.

Current treatment options in oncology 20070801

Farnesyltransferase inihibitors in hematologic malignancies.

Blood reviews 20070701

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

Blood 20070615

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.

Blood 20070515

The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.

Cancer research 20070515

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.

British journal of cancer 20070507

R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.

Journal of cellular physiology 20070501

Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra series.

European journal of medicinal chemistry 20070501

The incidence and impact of thrombocytopenia in myelodysplastic syndromes.

Cancer 20070501

A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.

Current medical research and opinion 20070501

Massive plexiform neurofibromas in childhood: natural history and management issues.

Journal of neurosurgery 20070501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070501

The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.

Leukemia 20070401

Diseases of large granular lymphocytes.

Cancer control : journal of the Moffitt Cancer Center 20070401

Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070401

Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.

Neoplasia (New York, N.Y.) 20070401

Clinical activity of tipifarnib in hematologic malignancies.

Expert opinion on investigational drugs 20070301

The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.

The oncologist 20070301

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070301

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

Blood 20070215

[Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].

Gan to kagaku ryoho. Cancer & chemotherapy 20070201

Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra MT).

Carcinogenesis 20070101

48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.

Clinical lymphoma & myeloma 20070101

E2902: A Phase III randomized study of farnesyl transferase inhibitor R115777 in acute myeloid leukemia patients in second or subsequent remission or in remission after primary induction failure or patients over age 60 in first remission.

Clinical advances in hematology & oncology : H&O 20070101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070101

Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.

Breast cancer research : BCR 20070101

Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex.

BMC genomics 20070101

New and old treatment modalities in primary myelofibrosis.

Cancer journal (Sudbury, Mass.) 20070101

Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT).

Carcinogenesis 20061201

Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes.

Therapeutics and clinical risk management 20061201

Role of erlotinib in the management of pancreatic cancer.

Therapeutics and clinical risk management 20061201

Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib.

Cancer chemotherapy and pharmacology 20061101

A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology 20061101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20061101

Depletion of substrates for protein prenylation increases apoptosis in human periovulatory granulosa cells.

Molecular reproduction and development 20061001

Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer.

Journal of clinical pharmacology 20061001

Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20061001

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?

British journal of cancer 20060918

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20060901

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060801

Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets.

Carcinogenesis 20060701

Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.

Investigational new drugs 20060701

Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060701

HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway.

Cancer research 20060701

Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients.

British journal of clinical pharmacology 20060701

Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.

British journal of cancer 20060424

Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib.

The Journal of pharmacology and experimental therapeutics 20060401

[Farnesyl transferase inhibitors--a novel agent for breast cancer].

Ai zheng = Aizheng = Chinese journal of cancer 20060401

Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations.

Molecular cancer therapeutics 20060401

[Molecular targets in colon cancer].

Therapeutische Umschau. Revue therapeutique 20060401

Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

British journal of cancer 20060327

Tipifarnib: farnesyl transferase inhibition at a crossroads.

Expert review of anticancer therapy 20060301

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20060301

Farnesyltransferase inhibitors in myelodysplastic syndrome.

Current hematologic malignancy reports 20060301

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060120

Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

Non-transplant therapy for older adults with acute myeloid leukemia.

Journal of the National Comprehensive Cancer Network : JNCCN 20060101

Myelodysplasia: when to treat and how.

Best practice & research. Clinical haematology 20060101

Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.

Breast cancer research : BCR 20060101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20051201

Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.

Future oncology (London, England) 20051201

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.

British journal of cancer 20051128

In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.

Blood 20051115

Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro.

Leukemia & lymphoma 20051101

Farnesyl transferase inhibition in hematologic malignancies.

Journal of the National Comprehensive Cancer Network : JNCCN 20051101

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.

Investigational new drugs 20051001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20051001

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050920

Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells.

Frontiers in bioscience : a journal and virtual library 20050901

Development of farnesyl transferase inhibitors: a review.

The oncologist 20050901

The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease.

Journal of medicinal chemistry 20050825

Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.

Clinical cancer research : an official journal of the American Association for Cancer Research 20050815

Conventional and new treatment options for myelofibrosis with myeloid metaplasia.

Seminars in oncology 20050801

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

Blood 20050615

Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity.

Bioorganic & medicinal chemistry letters 20050602

Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.

Journal of medicinal chemistry 20050602

Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines.

Biochemical pharmacology 20050601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20050601

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.

Cancer 20050515

Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.

Blood 20050501

Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.

Current drug targets 20050501

Farnesyltransferase inhibitors in myelodysplastic syndrome.

Current hematology reports 20050501

Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.

Bioorganic & medicinal chemistry letters 20050415

Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.

Cancer research 20050401

In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy.

Nuclear medicine and biology 20050401

Current and future perspectives on fulvestrant.

Clinical breast cancer 20050401

Molecule of the month. Tipifarnib.

Drug news & perspectives 20050401

Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.

Anti-cancer drugs 20050301

[Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].

Bulletin du cancer 20050301

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20050301

Farnesyltransferase inhibitors.

Clinical advances in hematology & oncology : H&O 20050301

[New targets for molecular therapy of acute leukemia: a 'single-hit' or 'multiple-hit' strategy against signaling pathway].

Zhonghua yi xue za zhi 20050223

Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor.

Nuclear medicine communications 20050201

A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20050201

Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.

Current hematology reports 20050101

The American Society of Hematology--46th Annual Meeting and Exposition. HDAC, Flt and farnesyl transferase inhibitors.

IDrugs : the investigational drugs journal 20050101

New agents in intravesical chemotherapy of superficial bladder cancer.

Scandinavian journal of urology and nephrology 20050101

Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro.

Anticancer research 20050101

Farnesyltransferase inhibitors.

Cancer chemotherapy and biological response modifiers 20050101

New concepts in the treatment of acute myeloid malignancies: selected pathways for targeted therapy.

Journal of biological regulators and homeostatic agents 20050101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20050101

Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.

Breast cancer research : BCR 20050101

[Problems in the current target therapy of malignancies].

Voprosy onkologii 20050101

The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.

European journal of haematology 20041201

Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041201

Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors.

Bioorganic & medicinal chemistry letters 20041101

Synthesis and activity of 1-aryl-1'-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors.

Bioorganic & medicinal chemistry letters 20041101

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.

Leukemia & lymphoma 20041101

[Multiple myeloma: from molecular pathogenensis to the development of molecular targeting therapies].

[Rinsho ketsueki] The Japanese journal of clinical hematology 20041101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20041101

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041001

The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.

Oncogene 20040909

Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor.

British journal of pharmacology 20040901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040901

Quantile estimation following non-parametric phase I clinical trials with ordinal response.

Statistics in medicine 20040830

Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients.

Investigational new drugs 20040801

Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status.

Nuclear medicine and biology 20040801

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology 20040801

Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.

Experimental biology and medicine (Maywood, N.J.) 20040701

Farnesyltransferase inhibitors as anticancer agents: critical crossroads.

Current opinion in drug discovery & development 20040701

Farnesyl transferase inhibitors for patients with lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.

Biochemistry 20040608

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.

Cancer chemotherapy and pharmacology 20040601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040601

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.

Blood 20040501

Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome.

Current hematology reports 20040501

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.

British journal of cancer 20040419

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040401

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040401

Targeted therapies in myelodysplastic syndromes: ASH 2003 review.

Seminars in hematology 20040401

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040301

R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways.

Molecular cancer therapeutics 20040201

Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.

Journal of medicinal chemistry 20040129

[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].

[Rinsho ketsueki] The Japanese journal of clinical hematology 20040101

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia.

BMC cancer 20040101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040101

New targets for therapy in breast cancer: farnesyltransferase inhibitors.

Breast cancer research : BCR 20040101

[Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].

Wiadomosci lekarskie (Warsaw, Poland : 1960) 20040101

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.

Blood 20031215

4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.

Bioorganic & medicinal chemistry letters 20031215

Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors.

Bioorganic & medicinal chemistry letters 20031215

The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.

Clinical cancer research : an official journal of the American Association for Cancer Research 20031201

Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro.

Blood 20031101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20031101

A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research 20031015

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways.

Expert review of anticancer therapy 20031001

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.

Seminars in oncology 20031001

Farnesyl transferase inhibitors in myeloid malignancies.

Blood reviews 20030901

Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.

Leukemia 20030901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20030901

Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.

Clinical lung cancer 20030901

Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.

Clinical lymphoma 20030801

New drugs in acute myeloid leukemia.

Clinical advances in hematology & oncology : H&O 20030801

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030701

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20030601

5-imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors.

Bioorganic & medicinal chemistry letters 20030505

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030501

Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777.

Clinical cancer research : an official journal of the American Association for Cancer Research 20030501

In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.

Leukemia 20030501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20030501

Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.

Bioorganic & medicinal chemistry letters 20030407

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030401

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

Blood 20030301

Preclinical and clinical evaluation of farnesyltransferase inhibitors.

Current oncology reports 20030301

Farnesyl transferase inhibitors in the treatment of breast cancer.

Expert opinion on investigational drugs 20030301

Inhibiting Ras signaling in the therapy of breast cancer.

Clinical breast cancer 20030201

Molecular targeting therapy for cancer: the Twelfth International Symposium of the Hiroshima Cancer Seminar, November 2002.

Cancer science 20030201

Targeting RAS signalling pathways in cancer therapy.

Nature reviews. Cancer 20030101

The prolyl isomerase Pin1 in breast development and cancer.

Breast cancer research : BCR 20030101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20030101

Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.

Current topics in medicinal chemistry 20030101

Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.

Anticancer research 20030101

Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials.

International journal of radiation oncology, biology, physics 20030101

Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.

Seminars in oncology 20021201

[Innovative treatment in oncology].

Recenti progressi in medicina 20021101

[New data presented at ASCO 2002 concerning small cell bronchial cancer].

Revue de pneumologie clinique 20021101

Farnesyl transferase inhibitors as anticancer agents.

European journal of cancer (Oxford, England : 1990) 20020901

Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.

Leukemia 20020901

Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.

Anti-cancer drugs 20020901

Gateways to Clinical Trials.

Methods and findings in experimental and clinical pharmacology 20020901

[New therapeutic targets and strategies in lung cancer].

Archivos de bronconeumologia 20020801

Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor.

Drug metabolism and disposition: the biological fate of chemicals 20020701

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

International journal of cancer 20020701

Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra).

Oncology (Williston Park, N.Y.) 20020701

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020601

Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.

Clinical cancer research : an official journal of the American Association for Cancer Research 20020601

Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis.

Clinical orthopaedics and related research 20020401

Tipifarnib (Janssen Pharmaceutica).

Current opinion in investigational drugs (London, England : 2000) 20020201

Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors.

European journal of drug metabolism and pharmacokinetics 20020101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20020101

Agents targeting ras signaling pathway.

Current pharmaceutical design 20020101

Farnesyltransferase inhibitors in breast cancer therapy.

Cancer investigation 20020101

Current status of clinical trials of farnesyltransferase inhibitors.

Current opinion in oncology 20011101

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20011101

Farnesyltransferase inhibitors.

Seminars in oncology 20011001

Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes.

Seminars in hematology 20010701

Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.

Seminars in hematology 20010701

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

Blood 20010601

Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells.

British journal of cancer 20010301

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.

Anti-cancer drugs 20010301

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

Cancer research 20010101

Farnesylated proteins and cell cycle progression.

Journal of cellular biochemistry. Supplement 20010101